Canaccord Genuity reiterated a Buy rating and $70.00 price target on DexCom (NASDAQ: DXCM) following the company's announced FDA approval ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

After-Hours Stock Movers 12/20: (NKE) (DXCM) (UA) Higher; (SCS) (FDX) (UPS) Lower (more...)December 20, 2016 5:57 PM DexCom (DXCM) Announces FDA Approval of G5 Mobile CGM System December 20, 2016 4:10 PM FDA Approval of Dexcom’s Non-Adjunctive Indication Triggers a New Era in Diabetes ManagementDecember 20, 2016 4:01 PM UPDATE: FDA Expands Indication for DexCom's (DXCM) Continuous Glucose Monitor SystemDecember 20, 2016 2:46 PM UPDATE: Oppenheimer Upgrades DexCom (DXCM) to OutperformDecember 19, 2016 8:39 AM DexCom Announces Upcoming Conference PresentationDecember 19, 2016 8:00 AM